Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas - A Pediatric Brain Tumor Consortium study

Neuro-Oncology

Volumn 16, Issue 2, 2014, Pages 310-317

  Gururangan, Sridharan ^a   Fangusaro, Jason ^b   Poussaint, Tina Young ^c   McLendon, Roger E ^a   Onar Thomas, Arzu ⁱ   Wu, Shengjie ⁱ   Packer, Roger J ^e   Banerjee, Anu ^f   Gilbertson, Richard J ^d   Fahey, Frederic ^c   Vajapeyam, Sridhar ^c   Jakacki, Regina ^g   Gajjar, Amar ^d   Goldman, Stewart ^b   Pollack, Ian F ^g   Friedman, Henry S ^a   Boyett, James M ⁱ   Fouladi, Maryam ^h   Kun, Larry E ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ Cincinnati Children's Hospital Medical Center ^*  (United States)

Author keywords

bevacizumab; children; CPT 11; gliomas; recurrent

Indexed keywords

AMINOTRANSFERASE; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRINOTECAN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 2;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BRAIN BLOOD VOLUME; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; EPISTAXIS; FOLLOW UP; GLIOMA; HIP PAIN; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KNEE DISEASE; MAJOR SURGERY; MULTIPLE CYCLE TREATMENT; NEUROFIBROMATOSIS; NEUROIMAGING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RECTUM HEMORRHAGE; RECURRENT DISEASE; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT;

BEVACIZUMAB; CHILDREN; CPT-11; GLIOMAS; RECURRENT;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893111710     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not154     Document Type: Article

References (33)

1. Rickert CH,PaulusW. Epidemiologyof central nervous systemtumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001;17(9):503-511.
2. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2005. Source: Central Brain Tumor Registry of the United States, 2009. www.cbtrus.org.
3. Watson GA, Kadota RP, Wisoff JH. Multidisciplinary management of pediatric low-grade gliomas. Seminars in Radiation Oncol. 2001; 11(2):152-162.
4. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747-754.
5. Perilongo G. Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma. J Neurooncol. 2005;75(3):301-307.
6. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358-1363.
7. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273-286.
8. Sikkema AH, de Bont ES, Molema G, et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells. Neuropathol Appl Neurobiol. 2011;37(5):538-548.
9. Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma: is it much different from glioblastoma? Neuropathol Appl Neurobiol. 2010;36(7):636-647.
10. Gesundheit B, Klement G, Senger C, et al. Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. Med Pediatr Oncol. 2003;41(6):516-526.
11. Ellis LM. Bevacizumab. Nat Rev Drug Discov. 2005;Suppl:S8-S9.
12. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069-3075.
13. Gururangan S, Fangusaro J, Young Poussaint T, et al. Lack of efficacy of bevacizumab+ irinotecan in cases of pediatric recurrent ependymoma-a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2012;14(11):1404-1412.
14. Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacyand toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2012;60(5):776-782.
15. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52(7):791-795.
16. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271-278.
17. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713-718.
18. Jain RK. Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer. 2008;8(4):309-316.
19. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69-82.
20. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9(2): 161-168.
21. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17(5):1516-1525.
22. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Childrens Oncology Group Study. J Clin Oncol. 2007;25(29):4622-4627.
23. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan- VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.
24. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(4):401-409.
25. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J ClinOncol. 2007;25(30):4714-4721.
26. Kruer MC, Kaplan AM, Etzl MM Jr., et al. The value of positron emission tomography and proliferation index in predicting progression in low-grade astrocytomas of childhood. J Neurooncol. 2009;95(2): 239-245.
27. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788-1795.
28. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46(2):439-448.
29. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
30. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Childrens Oncology Group Study. J Clin Oncol. 2008;26(3):399-405.
31. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8): 465-477.
32. Hall AP, Westwood FR, Wadsworth PF. Review of the effects of antiangiogenic compounds on the epiphyseal growth plate. Toxicologic pathology 2006;34(2):131-147.
33. GenenTech Corporation. AvastinTM Product safety information. 2011.